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Neurocognitive symptoms are common in individuals with somatic symptom and related
disorders (SSRD), but little is known about the specific impairments in neurocognitive
domains in patients with conversion disorder (CD)/functional neurological disorder
(FND). This study examines neurocognitive functioning in patients with CD/FND
compared to patients with other SSRD. The sample consisted of 318 patients. Twenty-
nine patients were diagnosed with CD/FND, mean age 42.4, standard deviation
(SD) = 13.8 years, 79.3% women, and 289 patients had other SSRD (mean age 42.1,
SD = 13.3, 60.2% women). Patients completed a neuropsychological test battery that
addressed a broad range of neurocognitive domains, including information processing
speed, attention and executive functioning. Patients with CD/FND had clinically
significant neurocognitive deficits in all neurocognitive domains based on normative data
comparison. Patients with CD/FND also performed significantly worse than patients with
other SSRD on information processing speed (Digit Symbol Substitution Test (V = .115,
p = .035), Stroop Color–Word Test (SCWT) card 1 (V = .190, p = .006), and SCWT
card 2 (V = .244, p < .001). No CD/FND vs. other SSRD differences were observed in
other neurocognitive domains. These findings indicate the patients with CD/FND
perform worse on information processing speed tests compared to patients with other
SSRD.
Conversion disorder (CD)/functional neurological disorder (FND) as defined in theDSM-5
is characterized by the presence of one or more deficits in voluntary motor or sensory
functions, which causes significant suffering and a burden of disease in multiple areas of
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daily life. Additionally, these symptoms cannot be explained by a neurological or other
medical condition (American Psychiatric Association (APA), 2013). Patients can display
symptoms of motor weakness, abnormal muscle contractions, loss of sensory functions,
and/or non-epileptic seizures (Kozlowska et al., 2015; Krem, 2004). The Diagnostic and
Statistical Manual of Mental Disorders – fifth edition (DSM-5) (APA, 2013) classifies CD/
FND among the somatic symptom and related disorders (SSRD) (APA, 2013). Other
categories of SSRD are somatic symptom disorder, illness anxiety disorder, factitious
disorder, psychological factors affecting other medical conditions, and other somatic
symptom and related disorders (APA, 2013).
The prevalence of CD/FND is approximately 0.7–5.0% (Uijen & Bischoff, 2011) and is
more common among women than men (Feinstein, 2011; Krem, 2004; Uijen & Bischoff,
2011)with a typical onset between the ages of 10–35 (Uijen&Bischoff, 2011). Risk factors
for CD/FND are depression, psychological or physical trauma, and loweducation (Uijen&
Bischoff, 2011). A common factor concerning demographic correlates of adult patients
with CD/FND is a lower level and/or fewer years of education (Binzer, Andersen, &
Kullgren, 1997; Deka, Chaudhury, Bora, & Kalita, 2007; Kuloglu, Atmaca, Tezcan, Gecici,
& Bulut, 2003; Kuwabara et al., 2007; Templer & Lester, 1974), compared to either
healthy individuals or people with other SSRD. Psychiatric comorbidity is frequently
present in CD/FND, including depression, pain disorders, and personality disorders
(Binzer, Andersen & Kullgren, 1997; Krem, 2004). Furthermore, physical stressors (e.g.,
injury to the concerned limb) also seem to function as a trigger in CD/FND (Stone,
Warlow, & Sharpe, 2012). Although conflicts and stressors often contribute to the
development and persistence of CD/FND (Feinstein, 2011; Nicholson et al., 2016), there
is substantial variability in the factors contributing to the aetiology of CD/FND (Ludwig
et al., 2018).
Recent studies have shown that CD/FND is associated with neurocognitive impair-
ments in several domains. Deficits and impairments have been documented in attention
(Brown, Nicholson, Aybek, Kanaan, & David, 2014; Demir, Celikel, Taycan, & Etikan,
2013; Kozlowska et al., 2015), learning (Demir et al., 2013), auditory–verbal memory
(Brown et al., 2014), (working) memory (Brown et al., 2014; Demir et al., 2013;
Kozlowska et al., 2015), executive functioning (Brown et al., 2014; Demir et al., 2013;
Kozlowska et al., 2015), and visuospatial functioning (Demir et al., 2013). A limitation of
these studies concerns methodological and research design-related issues. For example,
different neuropsychological tests have been used to assess neurocognitive functioning
and psychiatric comorbidity has not been taken into account systematically. The results of
these studies should therefore be interpreted with caution. Because psychiatric
comorbidity is common in CD/FND and other SSRD, particularly depression and anxiety
(Binzer et al., 1997; Henningsen, Zimmermann, & Sattel, 2003; Krem, 2004; Van Eck van
der Sluijs, TenHave, Rijnders, VanMarwijk, DeGraaf, &Van der Feltz-Cornelis, 2015), and
these comorbid conditions are also accompanied by neurocognitive dysfunction in
multiple domains (Castaneda, Tuulio-Henriksson, Marttunen, Suvisaari, & Lonnqvist,
2008; Lee, Hermens, Porter, &Redoblado-Hodge, 2012; Rock, Roiser, Riedel, &Blackwell,
2014; Tempesta, Mazza, Serroni, Moschetta, Di Giannantonio, & Ferrara, 2013), these
conditions may add to neurocognitive dysfunction in CD/FND and other SSRD (De
Vroege, Timmermans, Kop, & Van der Feltz-Cornelis, 2018).
Research on neurocognitive impairment in patients with CD/FND has typically used
normative data or non-psychiatric (healthy) comparison groups without taking concur-
rent physical complaints into consideration. It is therefore not knownwhether the nature
and severity of these impairments differ from neurocognitive functioning in patients with
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other SSRD. For instance, somatization and multiple functional somatic symptoms can
cause impairments in semantic memory as well as verbal episodic memory, visuospatial
functioning, psychomotor speed, and attention (Hall, Kuzminskyte, Pedersen, Ornbol, &
Fink, 2011; Niemi, Porti, Aalto, Hakala, & Karlsson, 2002). Patients with chronic pain also
show impairments in attention (Hart,Martelli, &Zasler, 2000;Moore, Keogh,&Eccleston,
2012), processing speed, psychomotor speed, and verbal fluency (Hart, Martelli, & Zasler,
2000). Patientswith undifferentiated somatoformdisorder are reported to performpoorly
on tasks involving working memory and executive functioning (Al-Adawi, Al-Zakwani,
Obeid, & Zaidan, 2010). Chronic fatigue syndrome can lead to impairments in processing
speed, working memory, and information learning (Michiels, & Cluydts, 2001). Patients
with fibromyalgia have been found to perform poorly on concentration tests, memory
tests, and tests of immediate and delayed recall (Grace et al., 1999). A recent study also
concluded that neurocognitive function in patients with SSRD is substantially reduced
across a broad array of cognitive domains (De Vroege et al., 2018). These investigations
indicate that individuals with SSRD-alike symptoms and SSRD are characterized by a wide
range of neurocognitive impairments and it is not establishedwhether the neurocognitive
problems in CD/FND are more profound than in patients with other SSRD.
This background indicates that systematic studies assessing a broad range of
neurocognitive domains in patients with CD/FND are limited in number and method-
ological quality. Furthermore, neurocognitive functioning in CD/FND has not yet been
directly compared with neurocognitive functioning in patients with other SSRD.
Therefore, this study will examine neurocognitive functioning in individuals with CD/
FND and compare them to patients with other SSRD. Considering the clinical features of
CD/FND, differences in severity of cognitive dysfunction are expected when comparing
to cognitive functioning of patients with other SSRD. We therefore examined neurocog-
nitive functioning in patients with CD/FND and to compare the findings with
neurocognitive functioning in patients with other SSRD. It was predicted that patients
with CD/FND will have problems in neurocognitive functioning, based on comparison
with population-based normative reference data. Based on earlier studies (Brown et al.,
2014; Demir et al., 2013; Kozlowska et al., 2015), these problems are expected especially
in the domains attention, (working) memory, planning/executive functioning, and
visuospatial functioning. Additionally, we expect that neurocognitive functioning in
patientswithCD/FNDwill be poorer compared to patientswith other SSRD and that these
differences are not accounted for by potential confounders (i.e., age, sex, level of
education, depression, and anxiety).
Methods
Design
This study used a cross-sectional design. First, neurocognitive functioning of patientswith
CD/FND was compared to neurocognitive functioning in the general population
normative reference data. Second, neurocognitive functioning of patients with CD/
FND was compared to neurocognitive functioning in patients with other SSRD. The
neuropsychological assessment (NPA) took place at the clinical centre of Excellence for
Body, Mind, and Health (CLGG), a department of a large mental health facility in the
Netherlands (GGz Breburg, Tilburg).
Data collection for this study was conducted from September 2013 to April 2017. All
patients were informed by letter before intake that their data could be used anonymously
for scientific research. Patients could indicate during intake if theydeclined theuseof their
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data for such purposes. In case patients declined the use of their data, this was recorded in
the administration system and the data of these patients were excluded from this study
(one patient declined the use of data for scientific research). Not consenting to use of their
data had no consequence on treatment at CLGG. The study protocol was approved by the
Scientific Review Committee of GGz Breburg (file number: CWO 2019-05).
Participants and diagnosis
Participantswere consecutive patients presentingwithCD/FNDorwith other SSRD at the
CLGG. Inclusioncriteria for thestudywereadiagnosisofeitherCD/FNDorSSRDaccording
to DSM-5 criteria and the ability to complete the NPA. Patients were excluded if they
evidenced malingering based on the tests for malingering, if they had insufficient
knowledgeof theDutch language,or ifpsychotic featuresoracute suicide riskwaspresent.
Diagnosis of CD/FND and other SSRD was based on clinical evaluation by one of the
psychiatrists using DSM-5 criteria and confirmed in the diagnostic multidisciplinary team
discussion. Before intake, referral letters from hospitals and medical specialists were
obtained and (re-) evaluated. These letters included information about electroencephalo-
grams (EEG), computer tomography (CT) scans, and magnetic resonance imaging (MRI)
scans that were made previously to obtain information regarding neurological substrates
for patients’ neurological symptoms.
Measures
Neuropsychological test battery
The primary outcome of this study is neurocognitive functioning. Patients were classified
as either having no neurocognitive problems (larger than or equal to the 20th percentile),
having a deficit (between the 2.4th and 20th percentile) or having a disorder (smaller than
the 2.4th percentile) (Lezak, Howieson, & Loring, 2012). Results of the neuropsycholog-
ical tests are categorized in the following domains: information processing speed,
attention, divided attention, memory, working memory, language, visuospatial function-
ing, and executive functioning.
Information processing speed. This domain was assessed using the subtest Digit
Symbol Substitution Test from the fourth edition of theWechsler Adult Intelligence Scale
(WAIS-IV;Wechsler, 2008), the Trail Making Test A (TMT-A; Reitan, 1992), and the Stroop
Color–Word Test (SCWT), card 1 and card 2 (Stroop, 1935). The WAIS Digit Symbol
Substitution Test examines information processing speed and psychomotor speed by
asking patients to fill in the corresponding symbols to the numbers presented on the piece
of paper (Wechsler, 2008). In subtest A of the TMT, patients are asked to connect the
presented numbers in ascending order (Reitan, 1992). The SCWT consists of three cards
(Stroop, 1935). In card 1, patients read aloud a list of the words red, green, blue, and
yellow. In card 2, patients read aloud the colour of the presented boxes.
Divided attention. Divided attention was assessed using subtest B of the TMT (Reitan,
1992). In subtest B, patients not only have to connect numbers, but also have to connect
letters in ascending order, constantly shifting from number to letter.
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Attention. Selective attention was assessed using card 3 of the SCWT (Stroop, 1935). In
card 3, patients are requested to read aloud the ink of the words (red, green, blue, and
yellow). Sustained attentionwas assessedusing the d2 (Brickenkamp,H€angsen,Merten,&
H€angsen, 2007). In this test, patients are asked to cancel out all ‘d’s’ with a total of two
dashes either above or below the letter. There are a total of 14 rows, with a time limit of
20 s per row. The score on concentration performance (CP) was used for analyses,
assessed as the number of correctly cancelled ‘d’s’ minus the incorrectly cancelled
symbols (Brickenkamp et al., 2007).
Executive functioning. Planning was assessed using the subtests of the Behavioral
Assessment of the Dysexecutive Syndrome (BADS; Wilson, Alderman, Burgess, Emslie, &
Evans, 1996): Key Search and Zoo Map. The Key Search subtest examines planning and
strategy by asking patients to draw a route in a square on a piece of paper they would
follow to find their lost key (Wilson et al., 1996). The subtest ZooMap examines complex
planning and strategy by asking patients twice to draw a route theywould follow to visit all
animals presented on the list. In the first condition, patients are simply asked to visit the
animals in the instruction. In the second condition, the order in which patients have to
visit the animals is provided and patients have to follow that order (Wilson et al., 1996).
Verbal fluency was measured using semantic and phonological verbal fluency tests
(Deelman, Koning-Haanstra, Liebrand, & Van der Burg, 1981). Patients are asked to name
asmuchwords as possible for oneminute startingwith a certain letter (N and A), followed
by naming as much animals as possible for two minutes (Deelman et al., 1981).
To assess cognitive flexibility, the Rule Shift Cards subtest of the BADS was used
(Wilson et al., 1996). The Rule Shift Cards subtest measures rule learning and rule shifting
by asking patients to respond to a series of cards according to two presented rules.
Working memory. This domain was assessed using the WAIS-IV Digit Span (Wechsler,
2008). The Digit Span subtest consists of three trials, in which patients are asked to
verbally repeat given numbers in the same order, in reverse order, or in ascending order,
respectively.
Memory. Verbal memory was assessed using the Rey Auditory Verbal Learning Test
(RAVLT) and the Rivermead Behavioural Memory Test (RBMT). The RAVLT (Saan &
Deelman, 1986) examines auditory–verbal memory by having patients remember and
repeat 15 unrelatedwords, during a total of five trials. After 15–20 min, patients are asked
to name all thewords from that list they remembered (Saan &Deelman, 1986). The RBMT
measures contextualmemory by reading aloud twonewspaper stories to patients (one at a
time), after which they have to repeat the stories immediately, and repeat them again after
15 min (Wilson, Cockbum, & Baddeley, 1985).
Visual memory was assessed using the Rey–Osterrieth Complex Figure Test (ROCFT),
immediate and delayed recall (Osterrieth, 1944). The test examines visual memory and
visuospatial construction by asking patients to copy a complex figure, and subsequently
reproduce the figure from memory. After 30 min, patients again have to reproduce the
figure frommemory. The total scores on these testswere converted into percentile scores.
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Language. Language-related functioning was assessed using the Boston Naming Test
(BNT) and the verbal fluency test. The BNT examines confrontational word retrieval by
having patients name or describe the presented pictures (Kaplan, Goodglass, &
Weintraub, 2001).
Visuospatial construction. Visuospatial construction was assessed using the ROCFT
(Osterrieth, 1944). Patients are asked to copy a complex figure, consisting on 18
identifiable areas. Those areas are scored with regard to the accuracy of the position,
distortion, and/or absence of an area. A total score of 36 is themaximumscorepatients can
achieve.
Demographic and clinical covariates
Demographic variables (age, sex, education) and clinical variables (depression, anxiety)
were obtained during intake. The level of education was classified using the ‘Verhage
coding scale’ (Verhage, 1964) and divided into low (Verhage 1–4), average (Verhage 5),
and high (Verhage 6–7).
Depression and Anxiety assessment
Depression and anxiety were assessed during the stand PROM at intake. Depression was
measured using the Patient HealthQuestionnaire-9 (PHQ-9; Kroenke, Spitzer, &Williams,
2001). This self-report scale consists of nine items to measure depression severity. A cut-
off score of 10 was used to detect depression (Kroenke et al., 2016), which had good
psychometric properties (sensitivity and specificity of 88%). The Generalized Anxiety
Disorder-7 (GAD-7; Spitzer, Kroenke, Williams, & Lowe, 2006) was used to measure
anxiety. This self-report questionnaire consists of seven itemsmeasuring the frequency of
anxiety symptoms during the last two weeks. The psychometric properties of the GAD-7
are good (Cronbach’s a = .8 to .9) (Spitzer et al., 2006). A cut-off score of 10 on theGAD-7
was used to detect anxiety (Kroenke et al., 2016). These questionnaires were obtained as
part of routine outcome monitoring.
Statistical methods
We examined descriptive statistics for demographic (e.g., age, sex, education level) and
clinical variables (e.g., depression, anxiety) for the patients with CD/FND, patients with
other SSRD and the total sample. Differences in demographic and clinical variables
between the CD/FND and other SSRD patient groups were explored using chi-square test
and Cramer’s V or independent-samples t-test (and Cohen’s d) for categorical variables
and continuous variables, respectively.
To test if the raw scores of the NPA tests were normally distributed, the Shapiro–Wilk
test and Kolmogorov–Smirnov test were used in addition to visual inspection of the
frequency histograms of each variable.
To compare patients with CD/FND with normative values, all raw scores were
transformed into percentile scores by using the available norm scores. Patients were then
classified as either having no neurocognitive problems (larger than or equal to the 20th
percentile), having a deficit (between the 2.4th and 20th percentile) or having a disorder
(smaller than the 2.4th percentile) (Lezak et al., 2012).
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To compare the CD/FND with the SSRD groups with respect to neurocognitive
functioning, independent t-tests (for normally distributed data) and the Mann–WhitneyU
test (for non-normally distributed data) and the raw NPA test scores. Cohen’s d values are
presented as index of effect size.
Multivariate analysis of variance (MANOVA) was conducted to examine whether
depression or anxiety displayed an additional association with neurocognitive function-
ing in CD/FND. Because log transformations did not result in normal distribution, raw
scores that deviated from normal were used for MANOVA. If an association for an overall
MANOVAeffectwas observed, subsequent hierarchicalmultiple regression analyseswere
used to adjust for sex, age, education level, depression and anxiety (as categorical
variables; analyses using continuous variables yielded the same results) with the
neuropsychological tests that differed significantly between CD/FND and other SSRD as
dependent variable. IBM Statistical Package for the Social Sciences Statistics 22.0 (IBM
Corporation, 2013) was used for statistical analyses.
Results
Patient characteristics
Table 1 provides an overview of the patient characteristics, for both the total sample and
differentiated by patients with CD/FND and those with other SSRD. Of the total sample of
318 patients, 61.9% were women, and patients had a mean age of 42.1 (SD = 13.3). A
diagnosis of CD/FNDwas made in 29 (9.1%) patients, and 289 (90.9%) patients had other
SSRD. Most of the patients were married, or had a registered partner, had an average level
of education, and were not able to work due to physical complaints. 6.9% of the CD/FND
group was suspected of malingering, compared to 7.3% of the other SSRD group. Further
analyses were conducted using the total sample after the exclusion of patients who were
suspected of malingering (N = 295).
A total of 29 patientswere diagnosedwithCD/FNDofwhich 6patients presentedwith
psychogenic non-epileptic attacks, seven patients suffered from periods of unrespon-
siveness (including loss of speech) and 16 patients showed either weakness/paralysis or
loss of sensation in extremities. These symptomswere evaluated previously in all patients
with either EEG, CT scan,or MRI scan at a neurology department and/or an academic
centre of epileptology. Regarding the 289 patients with other SSRD, two patients were
diagnosed with factitious disorder, two with unspecified psychological disorder by a
somatic disease, 23 patients were diagnosed with an illness anxiety disorder, and 262
patients were diagnosed with a somatic symptom disorder.
Sex differed significantly between patients with CD/FND and other SSRD (d = .11,
p = .043). Mean scores on the PHQ-9 and GAD-7 did not differ significantly between
patients with CD/FND and other SSRD.
Neurocognitive functioning in patients with conversion disorder
Table 2 provides an overview of neurocognitive functioning for each cognitive domain in
patients with CD/FND. Compared to population-based normative reference data,
combined deficits/disorders (i.e., scoring below the 20% percentile compared to
normative values) were found in the domains information processing speed (Digit
Symbol Substitution Test: 65.4%, TMT-A: 55.5%, SCWT card 1: 88.5%, and SCWT card 2:
76.0%), divided attention (TMT-B: 36.0%), selective attention (SCWT card 3: 12.0%),
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sustained attention (d2: 52.2%), and working memory (WAIS Digit Span: 51.8%). Patients
with CD/FND also had impaired verbal memory based on the RALVT immediate (37.0%)
and delayed (40.7%) recall, and the RBMT Story Recall immediate (23.1%) and delayed
Table 1. Descriptive statistics of total sample and differentiated by CD/FND and SSRD
Total sample CD/FND Other SSRD
ES
(N = 318) (N = 29) (N = 289)
n (%)/M (SD) n (%)/M (SD) n (%)/M (SD)
Age (years) 42.1 (13.3) 42.4 (13.8) 42.1 (13.3) .02
Sex
Woman 197 (61.9%) 23 (79.3%) 174 (60.2%) .11*
Education levela
Low (Verhage 1–4) 83 (26.1%) 11 (37.9%) 72 (24.9%) .13
Average (Verhage 5) 131 (41.2%) 14 (48.3%) 117 (40.5%)
High (Verhage 6–7) 98 (30.8%) 4 (13.8%) 94 (32.5%)
Missing 6 (1.9%) 0 (0.0%) 6 (2.1%)
Marital status
Married/Registered partnership 123 (38.7%) 13(44.8%) 110 (38.1%) .07
Partner 78 (24.5%) 7 (24.1%) 71 (24.6%)
Single 88 (27.7%) 7 (24.1%) 81 (28.0%)
Living with parents 6 (1.9%) 1 (3.4%) 5 (1.7%)
Missing 23 (7.2%) 1 (3.4%) 22 (7.6%)
Work status
Full-time/Part-time 60 (18.9%) 2 (6.9%) 58 (20.1%) .14
Unemployed/Retired 66 (20.8%) 9 (31.0%) 57 (19.7%)
Cannot work due to physical complaints 117 (36.8%) 13 (44.8%) 104 (36.0%)
Studying 6 (1.9%) 1 (3.4%) 5 (1.7%)
Different/Unknown 69 (21.7%) 4 (13.8%) 65 (22.5%)
Malingering
Yes 23 (7.2%) 2 (6.9%) 21 (7.3%) .09
No 256 (80.5%) 26 (89.7%) 230 (79.6%)
No malingering tests assessed 39 (12.3%) 1 (3.4%) 38 (13.1%)
Psychological measures
Depressive symptoms (PHQ-9)
Mean score PHQ-9 14.3 (6.1) 14.4 (6.5) 14.3 (6.0) .02
Missing 2
Positive for depression 242 (76.1%) 22 (75.9%) 220 (76.1%) .01
No depression 74 (23.3%) 7 (24.1%) 67 (23.2%)
No PHQ-9 assessed 2 (0.6%) – 2 (0.7%)
Anxiety (GAD-7)
Mean score GAD-7 11.6 (5.8) 10.1 (5.8) 11.8 (5.8) .29
Missing 2
Positive for Anxiety 197 (61.9%) 16 (55.2%) 181 (62.6%) .05
No anxiety 119 (37.4%) 13 (44.8%) 106 (36.7%)
No GAD-7 assessed 2 (0.6%) – 2 (0.7%)
Notes. GAD = General Anxiety Disorder; PHQ = Patient Health Questionnaire.
Total number of patients per group (N), number of patients per variable (n) with percentages (%), and
mean scores (M) with standard deviations (SD) per group are presented. Cramer’s V (chi-square) and
Cohen’s d (independent-samples t-test) were used to determine the effect size (ES).
aFollowing Verhage coding (57).
*p < .05 (two-tailed).
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Table 2. Neurocognitive functioning of patients with CD/FND (N = 29)
Neurocognitive domain
Raw scores Percentiles
M (SD) n (%)
Information processing speed
WAIS Digit Symbol Substitution Test (N = 26)
No neurocognitive problems
57.2 (19.1)
9 (34.6%)
Deficit 11 (42.3%)
Disorder 6 (23.1%)
TMT-A (N = 27)
No neurocognitive problems
43.2 (17.5)
12 (44.4%)
Deficit 10 (37.0%)
Disorder 5 (18.5%)
SCWT Card 1 (N = 26)
No neurocognitive problems
62.0 (15.1)
3 (11.5%)
Deficit 10 (38.5%)
Disorder 13 (50.0%)
SCWT Card 2 (N = 25)
No neurocognitive problems
79.6 (24.6)
6 (24.0%)
Deficit 4 (16.0%)
Disorder 15 (60.0%)
Attention
Divided attention: TMT-B (N = 25)
No neurocognitive problems
104.6 (60.2)
16 (64.0%)
Deficit 4 (16.0%)
Disorder 5 (20.0%)
Selective attention: SCWT Card 3 (N = 25)
No neurocognitive problems
124.8 (61.8)
22 (88.0%)
Deficit 3 (12.0%)
Disorder
Sustained attention: d2 (N = 23)
No neurocognitive problems
132.5 (46.1)
11 (47.8%)
Deficit 10 (43.5%)
Disorder 2 (8.7%)
Executive functioning
Planning
BADS Key Search (N = 27)
No neurocognitive problems
11.9 (4.3)
21 (77.8%)
Deficit 1 (3.7%)
Disorder 5 (18.5%)
BADS Zoo Map (N = 26)
No neurocognitive problems
11.5 (4.5)
24 (92.3%)
Deficit 2 (7.7%)
Disorder –
Verbal fluency
Phonological verbal fluency: N + A (N = 23)
No neurocognitive problems
18.2 (7.8)
12 (52.2%)
Deficit 11 (47.8%)
Disorder –
Semantic verbal fluency: animals (N = 25)
No neurocognitive problems
30.2 (8.1)
21 (84.0%)
Deficit 3 (12.0%)
Disorder 1 (4.0%)
Continued
Neurocognitive function in conversion disorder/FND 9
Table 2. (Continued)
Neurocognitive domain
Raw scores Percentiles
M (SD) n (%)
Memory processes
Working memory: WAIS Digit Span (N = 27)
No neurocognitive problems
22.2 (5.9)
13 (48.1%)
Deficit 8 (29.6%)
Disorder 6 (22.2%)
Storage of information
Verbal Memory: RALVT immediate recall (N = 27)
No neurocognitive problems
40.2 (11.7)
17 (63.0%)
Deficit 3 (11.1%)
Disorder 7 (25.9%)
Verbal Memory: RBMT immediate recall (N = 26)
No neurocognitive problems
16.4 (6.1)
20 (76.9%)
Deficit 6 (23.1%)
Disorder –
Retrieval of information
Verbal Memory: RALVT delayed recall (N = 27)
No neurocognitive problems
8.1 (3.7)
16 (59.3%)
Deficit 6 (22.2%)
Disorder 5 (18.5%)
Verbal Memory: RBMT delayed recall (N = 26)
No neurocognitive problems
12.7 (6.0)
19 (73.1%)
Deficit 5 (19.2%)
Disorder 2 (7.7%)
Visual Memory: ROCFT immediate recall (N = 26)
No neurocognitive problems
17.9 (7.7)
13 (50%)
Deficit 9 (34.6%)
Disorder 4 (15.4%)
Visual Memory: ROCFT delayed recall (N = 26)
No neurocognitive problems
16.0 (7.3)
12 (46.2%)
Deficit 6 (23.1%)
Disorder 8 (30.8%)
Language
Word retrieval: BNT(N = 25)
No neurocognitive problems
159.0 (13.4)
15 (60.0%)
Deficit 7 (28.0%)
Disorder 3 (12.0%)
Visuospatial construction
ROCFT copy (N = 26)
No neurocognitive problems
28.6 (6.4)
–
Deficit 18 (69.2%)
Disorder 8 (30.8%)
Notes. BADS, Behavioral Assessment of the Dysexecutive Syndrome; BNT, Boston Naming Test;
RAVLT, Rey Auditory Verbal Learning Test; RBMT, Rivermead Behavioural Memory Test; ROCFT, Rey–
Osterrieth Complex Figure Test; ROCFT, Rey–Osterrieth Complex Figure Test; SCWT, StroopColor–
Word Test; TMT, Trail Making Test; WAIS, Wechsler Adult Intelligence Scale.
Total number of patients per group (N), and number of patients per variable (n) with percentages (%) are
presented. Deficit = ≤20th percentile compared to normative values (but >2.4 percentile), disor-
der = ≤2.4 percentile compared to normative data.
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(26.9%) recall. Deficits/disorders were also found in visual memory according to the
ROCFT immediate and delayed recall (50.0% and 53.9%, respectively). 40.0% of the
patients had deficits/disorders within language (BNT). Executive functioning tests also
displayed deficits/disorders including problems with planning based on the BADS Key
Search (22.2%) and BADS ZooMap (7.7%), as well as phonological verbal fluency (47.8%),
and semantic verbal fluency (16.0%). Visuospatial construction (ROCFT copy: 100.0%)
and cognitive flexibility (BADS Rule Shift Cards: 15.4%) were also impaired.
Neurocognitive functioning in patients with conversion disorder versus patients with
other SSRD
Neurocognitive functioning of patients with CD/FND compared to patients with other
SSRD is described in Table 3. Patients with SSRD other than CD/FND displayed deficits in
14 out of the 21 neurocognitive tests. When comparing patients with CD/FND with
patients with other SSRD using non-parametric Mann–Whitney (U) tests (on the raw
scores),we found that patientswithCD/FNDperformed significantlyworse on the TMT-A
(U = 2,579.5, z = 2.243, p = .025, d = .31), SCWT card 1 (U = 1,816.5, z = 3.872,
p < .001, d = .82), card 2 (U = 1,928.5, z = 3.339, p = .001, d = .88), and card 3
(U = 2,375.5, z = 2.175, p = .030, d = .54), the ROCFT copy (U = 2,527.0,
z = 2.031, p = .042, d = .44), and the phonological part of the verbal fluency test
(U = 2,382.5, z = 2.010, p = .044, d = .45).
Analysis of potentially confounding variables revealed that depression was not
significantly associated with the neurocognitive measures that were different between
patients with CD/FND versus those with other SSRD (Wilks Lamba (F(21)= .901, p = .591,
partial eta squared = .083). Anxiety was also not significantly related to neurocognitive
measures that were different between patients with CD/FND versus those with other
SSRD, Wilks Lamba (F (21) = .765, p = .761, partial eta squared = .071. Therefore, no
further multiple regression analyses were conducted to explore the additional effect of
depression and anxiety on the neurocognitive domains in patients with CD/FND.
Discussion
This study shows that patients with CD/FND show substantial neurocognitive impair-
ments (i.e., disorders and deficits combined) compared to population level, within the
domains of information processing speed, attention, executive functioning, (working)
memory, and language. No impairments were found in visuospatial functioning in
patients with CD/FND, which is in contrast with our a priori expectations. Compared to
patients with other SSRD, patients with CD/FND showed significantly more impairment
in information processing speed. This findingwas in linewith our hypothesis. Depression
and anxiety, or education, age, and gender, did not play an important role in the
differences in neurocognitive functioning in patients with CD/FND versus those with
other SSRD.
When comparing the results of this study to the available literature, neurocognitive
impairments in the domains attention, working memory, verbal and visual memory,
visuospatial functioning, and information processing speed are commonly found in
patients with CD/FND (Brown et al., 2014; Demir et al., 2013; Kozlowska et al., 2015).
This study also adds dysfunction in the language domain to the list of impairments, which
are also found in the other SSRD group (Al-Adawi et al., 2010; Grace et al., 1999; Hall et al.,
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Table 3. Neurocognitive functioning of patients with CD/FND compared to other SSRD
Raw scores M (SD)
CD/FND Other SSRD Cohen’s d
Information processing speed
WAIS Digit Symbol Substitution Test 57.2 (19.1) 64.2 (17.6) .39
(Na) 26 251
TMT-A 43.2 (17.5) 37.3 (18.9) .31*
(Na) 27 259
SCWT Card 1 62.0 (15.1) 50.6 (13.8) .82***
(Na) 26 259
SCWT Card 2 79.6 (24.6) 63.9 (17.1) .88**
(Na) 25 259
Attention
Divided attention: TMT-B 104.6 (60.2) 82.5 (47.6) .45
(Na) 25 257
Selective attention: SCWT Card 3 124.8 (61.8) 102.4 (39.0) .54*
(Na) 25 258
Sustained attention: d2 132.5 (46.1) 144.3 (46.1) .26
(Na) 23 250
Working memory
WAIS Digit Span 22.2 (5.9) 24.4 (5.2) .42
(Na) 27 261
Storage of information (memory)
Verbal Memory: RALVT immediate recall 40.2 (11.7) 42.2 (10.8) .18
(Na) 27 261
Verbal Memory: RBMT Story immediate recall 16.4 (6.1) 17.1 (6.1) .11
(Na) 26 260
Retrieval of information
Verbal Memory: RALVT delayed recall 8.1 (3.7) 8.6 (3.1) .06
(Na) 27 262
Verbal Memory: RBMT Story delayed recall 12.7 (6.0) 13.9 (5.8) .21
(Na) 26 256
Visual Memory: ROCFT immediate recall 17.9 (7.7) 18.9 (7.0) .14
(Na) 26 253
Visual Memory: ROCFT delayed recall 16.0 (7.3) 18.5 (6.8) .37
(Na) 26 252
Language
Word retrieval: BNT 159.0 (13.4) 157.8 (16.3) .07
(Na) 25 260
Visuospatial construction
ROCFT copy 28.6 (6.4) 31.0 (5.3) .44*
(Na) 26 256
Executive functioning
Phonological verbal fluency: N + A 18.2 (7.8) 22.3 (9.2) .45*
(Na) 25 252
Semantic verbal fluency: animal naming 30.2 (8.1) 32.4 (8.9) .25
(Na) 25 252
Cognitive flexibility: BADS Rule Shift Cards 18.7 (2.7) 19.0 (2.4) .12
(Na) 26 252
Planning
Continued
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2011; Hart et al., 2000; Michiels & Cluydts, 2001; Moore et al., 2012; Niemi et al., 2002).
Our results show that patients with CD/FND have substantially impaired information
processing speed which may also influence other neurocognitive functions (Penke,
Maniega, Bastin, Valdes Hernandez, Murray, Royle, et al., 2012; Verhaeghen, 2014).
Regarding the neurobiological mechanisms that could play a role in these associations,
evidence suggests that brain areas that are linked to CD/FND include the supplementary
motor area, dorsolateral prefrontal cortex (dlPFC), and anterior cingulate cortex
(Ridderinkhof, Van den Wildenberg, Segalowitz, & Carter, 2004; Rubia, Russell,
Overmeyer, Brammer, Bullmore, & Sharma, 2001). In particular, the anterior cingulate
cortex is important for the cognitive and attentional aspect of the inhibitory responses as
measured using the Stroop Color–Word task (Rubia et al., 2001). The dlPFC is involved in
the decision-making process and selection of the responses by linking the representation
of short-termmemorywith goal-directedmotor behaviour (Ridderinkhof et al., 2004). The
cerebellum is one of the brain areas involved in inhibition ofmotor responses (Rubia et al.,
2001). However, the cerebellum is also an important brain area for other cognitive
functions, including attention, executive functioning, (working) memory, language, and
visuospatial regulation (Baillieux, De Smet, Paquier, De Deyn, & Marien, 2008). Thus,
there is a plausible interplay between motor and sensory symptoms of CD/FND, the
neurobiological correlates of CD/FND and neuropsychological functioning in the
domains of attention, inhibition, learning, (working) memory, executive functioning,
and visuospatial functioning. Evidence from this study suggests that basic information
processing speed may be disproportionately impaired in CD/FND versus other SSRD,
which may in part reflect supplementary motor areas as well as cerebellum dysfunction.
The findings of this study have implications for the treatment of CD/FND. In general,
the effectiveness of CBT remains equivocal (Conwill, Oakley, Evans, & Cavanna, 2014;
Goldstein et al., 2010; Kuyk, Siffels, Bakvis, & Swinkels, 2008; LaFrance et al., 2014) for
treating psychogenic non-epileptic seizures. A review of randomized controlled trials
(Kroenke, 2007) reported only two randomized controlled trials (RCT) which explored
the effect of hypnosis in patients with CD but showed limited effects (Moene, Spinhoven,
Hoogduin, & Van Dyck, 2002; Moene, Spinhoven, Hoogduin, & Van Dyck, 2003 ). Other
Table 3. (Continued)
Raw scores M (SD)
CD/FND Other SSRD Cohen’s d
BADS Key Search 11.9 (4.3) 11.9 (3.8) .00
(Na) 27 255
BADS Zoo Map 11.5 (4.5) 11.6 (4.0) .02
(Na) 26 250
Notes. BADS = Behavioral Assessment of the Dysexecutive Syndrome; BNT = Boston Naming Test;
RAVLT = Rey Auditory Verbal Learning Test; RBMT = Rivermead Behavioural Memory Test;
ROCFT = Rey–Osterrieth Complex Figure Test; SCWT = Stroop Color–Word Test; TMT = Trail
Making Test; WAIS = Wechsler Adult Intelligence Scale.
Mean scores (M) with standard deviations (SD), and number of patients per variable (n). Because all
planning tasks were not normally distributed, analyses were conducted using the Mann–Whitney U test.
Cohen’s d was used to determine the effect size (ES).
aTotal number of patients per group.
*p < .05; **p < .01; ***p < .001 (two-tailed).
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therapies, so-called ‘third wave’ therapies, in which mindfulness is incorporated as
psychotherapeutic elements are gaining evidence as effective interventions (Baslet &Hill,
2011; Carlson & Perry, 2017). Concluding, evidence-based treatments for CD/FND are
scarce and require further studies.
Nevertheless, the effect of therapy may be limited in cases in which patients with CD/
FND also experience problems with information processing speed. For instance, CBT
sessions are harder to follow, and the information consolidation during the treatment
session is limited due to impaired information processing speed which also limits the
information retrieval after the treatment session. In that sense, problems in neurocog-
nitive functioning might negatively influence treatment outcomes. Focusing on
neurocognitive problems by using a cognitive rehabilitation therapy (CRT) can provide
a useful tool to support neurocognitive problems in CD/FND patients with cognitive
impairment (De Vroege, Khasho, Foruz & Van der Feltz-Cornelis, 2017) but also improve
motor symptoms and mental disorders. As a result, the neurocognitive symptoms of
patients with CD/FND can be of great burden andmay play a pivotal rolewithin treatment
Nevertheless, neurocognitive problems may be overcome in a preliminary stage before
the start of CBT by using CRT (Laatsch & Krisky, 2006).
Cognitive rehabilitation therapy is a treatment that is used successfully in patientswith
brain injury for a long time and is a standard approach for this patient population (Laatsch
& Krisky, 2006). A study combining CRT with functional magnetic resonance imaging
(fMRI) activity in traumatic brain injury patients reported both improvements in
neurocognitive functioning and increased activity in almost all brain areas similar to
healthy controls and activation of other brain areas after CRT (Laatsch & Krisky, 2006).
These preliminary results show that CRT has great potential with regard to improvement
of neurocognitive functioning and the activity of involved brain areas. A recent case study
already showed that using CRT in a patient with CD/FND not only contributed to better
neurocognitive functioning, but also improved motor symptoms and mental disorders
(De Vroege et al., 2017). However, more research on effectivity of CRT in patients with
CD/FND has yet to be conducted. Future studies are needed to evaluate improvements in
neurocognitive functioning after CRT and to establish the effect of CRT on CD/FND
specific symptoms. Furthermore, the literature suggests a possible role of directing
attention towards symptoms as an important determinant of CD/FND symptomatology
(e.g., McIntosh, McWhirter, Ludwig, Carson, & Stone, 2017). Future studies are needed to
empirically investigate the consequences of diverting attention towards or away from
(neurocognitive) symptoms in patients with CD/FND.
Limitations and strengths
Interpretation of the present study findings needs to be considered in the context of
several limitations. The group of patientswith CD/FND is relatively small compared to the
group of patients with other SSRD. With regard to the neuropsychological battery, the
population-based normative reference data of the ROCFT copy only classified patients
with a maximum of >16th percentile. This potentially leads to confounding results, given
that patients can never be classified as having no neurocognitive problems and the
percentage of patients with impairment in both groups is 100%. Another limitation is the
use of data that did not follow thenormal distribution to conduct theMANOVA.Moreover,
potentially confounding factors such as medication use (e.g., oxycodone) (Cherrier,
Amory, Ersek, Risler, & Shen, 2009) and comorbid disorders (e.g., posttraumatic stress
disorder, attention deficit hyperactivity disorder) (Millan et al., 2012), which could have
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had an effect on neurocognitive functioning, were not taken into account. These
limitations are outweighed to some extent by several strengths of this study, including the
unique focus on neurocognitive functioning in CD/FND using other SSRD patients as
reference group, and the assessment of a large number of neurocognitive tests and broad
range of cognitive domains relevant to CD/FND.
Conclusions and recommendations for future research
This study documents impairments in neurocognitive functioning in patients with CD/
FND and compared these results to neurocognitive functioning of other SSRD patients.
We demonstrated that impairments in information processing speed may be dispropor-
tionately present in CD/FND versus other manifestations of SSRD, whereas other
neurocognitive problemsmay be common to all SSRD, including CD/FND (e.g., attention,
working memory, memory, language, visuospatial construction, and aspects of executive
functioning such as cognitive flexibility and planning. Furthermore, neurocognitive
dysfunctioningmay lead to less efficientCBT, the treatment of choice inCD/FND. If CBT is
negatively influenced by impaired cognitive functioning (i.e., patients forget the
information that was taught during session or forget to do homework), CBT may not be
the effective treatment that patients with CD/FND need. CRT, in order to overcome
neurocognitive problems, prior to CBT may offer a solution.
Future research on neurocognitive functioning in CD/FND compared to other SSRD
should include larger samples of patients with CD/FND. Comorbid disorders should also
be included in the study to examine the direct association of CD/FND or other SSRD with
impaired neurocognitive functioning. Furthermore, it is important to combine neurocog-
nitive functioning in CD/FND with neurobiological correlates in future studies by using
fMRI. Finally, to investigate whether CRT has positive effects on patients with CD/FND
suffering fromneurocognitive impairment, future studies are needed to explore the effect
of CRT onmental and physical health outcomes in intervention studies targeting patients
with CD/FND and other SSRD.
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